



Third Quarter 2026 Financial Results

October 29, 2026

Agenda



01 Welcome

Josh Brodsky

Vice President, Investor Relations

02 Overview

Yvonne Greenstreet, M.D.

Chief Executive Officer

03 Commercial Highlights

Tolga Tanguler

Chief Commercialization Officer

04 R&D and Pipeline Perspective

Pushkal Garg, M.D.

Chief Research & Development Officer

05 Financial Summary

Jeff Poulton

Chief Financial Officer

06 Q&A Session



Alnylam Forward-Looking Statements

This presentation contains forward-looking statements. Forward looking statements include statements regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding: the potential for continued growth of AMVUTTRA and Alnylam's ATTR-CM franchise; the potential for Alnylam to achieve durable TTR leadership and for AMVUTTRA to be a foundational treatment and the first-line treatment of choice in ATTR-CM; the potential for Alnylam's commercial initiatives and investments to broaden AMVUTTRA's prescriber base, drive adoption at scale, and ultimately increase patient starts and demand for AMVUTTRA; the potential for prescriber utilization of AMVUTTRA to deepen with experience; the significant opportunity for ex-US markets to support Alnylam's TTR global leadership ambitions; the potential for the ATTR-CM category to continue to grow and for such growth to be robust; the potential impact of any changes to the 340B Drug Pricing Program and payor utilization management policies such as step therapy requirements for AMVUTTRA or any of Alnylam's other products, and the potential for any actions taken by Alnylam to mitigate potential risks to patient access on account of such changes; the potential success of the TRITON-PN and TRITON-CM clinical trials of nudesiran and the potential for nudesiran to strength Alnylam's long-term TTR position; the potential for nudesiran to achieve regulatory approval for the treatment of hATTR-PN and/or ATTR-CM; the timeline for any potential launch of nudesiran in hATTR-PN and/or ATTR-CM; the potential for Alnylam to initiate a placebo-controlled, pivotal trial of brezosiran in 2027; the potential efficacy and safety of brezosiran for the treatment of Huntington's disease; the timing of initiation, completion of enrollment, or sharing of data from, any of Alnylam's clinical trials; the potential for any of the programs in Alnylam's pipeline to improve human health and create value in the years ahead; Alnylam's ability to build a more diversified, multi-franchise business; Alnylam's ability to achieve the goals in its *Alnylam 2030* strategy and to become the leading science-driven, fully integrated biopharmaceutical company and to maximize the potential of RNAi therapeutics for patients; and Alnylam's projected commercial and financial performance, including the expected range for 2026 of TTR net product revenues, Rare net product revenues, total net product revenues, net revenues from collaborations and royalties, and non-GAAP R&D and SG&A expenses, including statements regarding where Alnylam's actual results are expected to fall in relation to the expected range for any of these financial metrics.

Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its "*Alnylam 2030*" strategy; Alnylam's ability to successfully launch, market and sell Alnylam's approved products globally, including AMVUTTRA; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam's marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam's ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the "Risk Factors" filed with Alnylam's most recent periodic report (Quarterly Report on Form 10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

This presentation references non-GAAP financial measures. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies. Percentage changes in revenue growth at Constant Exchange Rates, or CER, is a non-GAAP financial measure which is presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. CER represents growth calculated as if the exchange rates had remained unchanged from those used during the prior fiscal year.



Overview

Yvonne Greenstreet, M.D.

Chief Executive Officer

Q3 2026 Results Summary



Financial Performance

\$1,292M
(+52% YoY)

**Q3 Total Net
Product
Revenues**

**\$4,700M
to \$5,100M**

**Reiterated 2026
Total Net Product
Revenue
Guidance**



TTR Leadership

\$1,150M
(+59% YoY)

**Q3 Total TTR
Net Revenues**

N ~2,250

TRITON-CM
ATTR-CM CLINICAL STUDY

**Upsized
Enrollment Target
for TRITON-CM**



Pipeline Progress

**Presented Promising Initial Phase 1
Results for Brezosiran (ALN-HTT02)¹**

- Mean reduction of CSF HTT of 60-64%
- Placebo-controlled pivotal trial to initiate in 2027²

**TTR Data at ESC 2026 Demonstrate
Compelling Vutrisiran Profile**

- Consistent benefit regardless of baseline tafamidis use
- Positive impact across multisystemic manifestations of ATTR-CM
- Consistent treatment effect across sexes

Alnylam 2030

Accelerating Innovation. Scaling Impact.



2030



Achieve Global TTR Leadership

BUILD A DURABLE TTR FRANCHISE

- Lead TTR market in revenue by 2030 and cumulatively across 5-year period
- Launch best-in-class, next-gen silencer, nudesiran, in PN by 2028 and CM by 2030



Grow Through Sustainable Innovation

DELIVER THERAPIES THAT PREVENT, HALT, OR REVERSE DISEASE

- Deliver 2+ new transformative medicines beyond TTR with blockbuster potential
- Expand to 10 tissue types and > 40 clinical programs
- Invest ~30% of revenues in non-GAAP R&D, including select external innovation



Scale with Discipline & Agility

DRIVE SUSTAINED, PROFITABLE GROWTH

- Achieve 25%+ total revenue CAGR through YE 2030
- Deliver ~30% non-GAAP operating margin



Commercial Highlights

Tolga Tanguler

Chief Commercialization Officer

Commercial Performance in Q3 2026

Q3 2026 Overall Portfolio

\$1.29B

Combined Net Product Revenues

+52%

YoY growth¹
vs. Q3'25

+10%

QoQ growth¹
vs. Q2'26

TTR Franchise

Rare Franchise

amvuttra
(vutrisiran) injection
25 mg/0.5 mL


onpattro
(patisiran) lipid complex injection
10 mg/5 mL

GIVLAARI[®]
(givosiran) injection for subcutaneous use
189 mg/mL

OXLUMO[®]
(lumasiran) for injection
94.5 mg/0.5 mL

¹ With FX impact. For growth at CER = constant exchange rate – see the Financial Summary slide for more information.

ATTR-CM Launch Continues to Fuel Franchise Growth



amvuttra
(vutrisiran) injection
25 mg/0.5 mL

onpattro
(patisiran) lipid complex injection
10 mg/5 mL

Q3 2026 TTR Franchise Highlights

	QoQ % Growth	YoY % Growth
U.S.	12%	69%
ROW	10%	28%
Global	12%	59%

Q3'26 vs. Q2'26 (QoQ) Highlights

- U.S. 12% increase driven by \$81M in demand growth, a \$17M inventory benefit (ending inventory: Q2 19 days, Q3 21 days), and a modest increase in net price as Q3 was aided by ~\$10M in beneficial one time gross-to-net adjustments
- ROW 10% increase driven primarily by growth from ongoing ATTR-CM launches in Germany, Italy, and Japan, as well as the timing of orders in partner markets

Q3'26 vs. Q3'25 (YoY) Highlights

- U.S. 69% increase driven by strong demand growth from ATTR-CM launch offset modestly by lower net price
- ROW 28% increase primarily driven by uptake in ATTR-CM sales in Japan and Germany offset by lower CM pricing in launch markets

Expanding AMVUTTRA Utilization & Reach in a Growing U.S. TTR Market

Category Growth

~37%

ATTR-CM Category TRx volume growth Q3'26 vs Q3'25

~70% growth since March '25

And yet, ~80% of ATTR-CM patients remain untreated

Prescriber Expansion

>2,000

New, unique AMV prescribers added since March '25

Balanced utilization across COE & community settings

AMVUTTRA Total Rx Share in ATTR (TRx)

~24%

TRx share (*total* prescriptions, including new starts + continuing patient refills) in ATTR (PN/CM), through Q3'26

Fueled by depth + expanding breadth of HCP prescriber base



Committed to Patient Access

Options Exist to Mitigate Access Risks Resulting From Potential 340B Reimbursement Changes

CMS Proposal

- Proposed rule change would reduce hospital outpatient reimbursement for Part B medicines acquired by 340B institutions
- Final rule expected imminently; effective January 1, 2027, if implemented
- Anticipate legal challenges

Potential Provider Responses

- Continue traditional 340B purchasing
- Shift to WAC purchasing
- Utilize alternative site-of-care strategies (e.g., home care, 3rd party infusion clinics)

Alnylam Approach

- Options to address potential risks to patient access focused on:
 - Maintaining health system access via contracting
 - Enabling alternative sites of care

Committed to Patient Access

Today, patients
have broad and
favorable
access to
AMVUTTRA



~99%

of covered lives
have access; large
majority in 1L



~90%


of patients can access
treatment within ~10
miles of home

Most pay \$0 in out-of-pocket costs

R&D and Pipeline Perspective

Pushkal Garg, M.D.

Chief Research & Development Officer



Strongly Positioned for Durable TTR Leadership

AMVUTTRA

HELIOS-B Data Support AMVUTTRA as the First-Line Treatment of Choice in ATTR-CM

Consistency in effect across endpoints and subgroups reinforces our conviction in AMVUTTRA as a foundational treatment in ATTR-CM.

NUCRESIRAN

Learnings from CARDIO-TTRansform Strengthen Our Conviction in TRITON-CM

TRITON-CM combines the depth of TTR knockdown, patient population and study design required to maximize the probability of success.

Key Learnings from CARDIO-TTRansform



**Less
TTR Knockdown**



**More Advanced
Patient Population**



**Suboptimal
Endpoint Selection**



TRITON-CM: Optimized for Success & Broad Patient Impact

Enriched for patient population most likely to benefit

- BNP limits specified in inclusion/exclusion criteria

Event-driven outcomes study

- Primary composite of all-cause mortality and recurrent cardiovascular events



Enrollment expanded from N ~1,750 to ~2,250

- Ensures adequate study power under conservative estimates of outcome event rates
- Expansion further enriched for patients with early disease, expected to experience greatest benefit
- Largest study to-date in ATTR-CM

Launch timeline intact; expected by 2030

- Ample time to amend statistical analysis plan, if needed



Industry Leading Pipeline of RNAi Therapeutics

			PHASE 1	PHASE 2	PHASE 3
TTR	Nucresiran	~2	ATTR Amyloidosis with Cardiomyopathy		
	Nucresiran	~2	hATTR Amyloidosis with Polyneuropathy		
CARDIOVASCULAR	Zilebesiran ²	~2	Hypertension		
	Zilebesiran REVERSIR ²	~2	Hypertension		
METABOLIC	ALN-4324 (GRB14)	~2	Type 2 Diabetes Mellitus		
	Rapirosiran (ALN-HSD) ¹		Metabolic Dysfunction-Associated Steatohepatitis (MASH)		
	ALN-PNP ¹		Metabolic Dysfunction-Associated Steatohepatitis (MASH)		
	ALN-CIDEB ¹		Metabolic Dysfunction-Associated Steatohepatitis (MASH)		
	ALN-ANG3 ¹		Diabetic Kidney Disease		
	ALN-2232 (ACVR1C)	~2	Obesity & Weight Management		
	ALN-6222 (INHBE)	~2	Obesity & Weight Management		
	ALN-APOC3 ¹		Dyslipidemia		
NEUROSCIENCE	Cemdisiran ¹		Myasthenia Gravis		
	Mivelsiran	~2	Cerebral Amyloid Angiopathy		
	Mivelsiran	~2	Alzheimer's Disease		
	ALN-SOD ³	~2	SOD1 Amyotrophic Lateral Sclerosis		
	Brezosiran (ALN-HTT02) ⁴	~2	Huntington's Disease		
	ALN-5288 (MAPT) ⁴	~2	Alzheimer's Disease		
	ALN-SNCA ¹		Parkinson's Disease		
HEMATOLOGY	Cemdisiran ¹		Paroxysmal Nocturnal Hemoglobinuria		
	ALN-6400 (PLG)	~2	Hereditary Hemorrhagic Telangiectasia		
	ALN-6400 (PLG)	~2	Von Willebrand Disease		
	AG-236 (ALN-TMP) ¹		Polycythemia Vera		
	ALN-CFB ¹		Paroxysmal Nocturnal Hemoglobinuria		
OTHER	Cemdisiran ¹		Geographic Atrophy		
	Elebsiran ¹		Hepatitis D Virus Infection		
	ALN-BCAT	~2	Hepatocellular Carcinoma		
	ALN-4285	~2	Healthy Volunteers		
	ALN-4915	~2	Healthy Volunteers		
	ALN-F1202 ¹		Healthy Volunteers		

¹ Out-licensed with milestones and/or royalties; ² Partnered, Alnylam-led development with U.S. profit split and milestones/royalties ex-U.S.; ³ Partner-led with profit split; ⁴ Partnered, Alnylam-led with profit split; ~2 Alnylam-owned, -led, or -co-developed

Huntington's Disease (HD) Robs Generations of Patients of Body and Mind

Progressive, Fatal Monogenic Neurodegenerative Disease


Movement: chorea, incoordination, falls

Thinking: executive dysfunction, memory loss

Mood: depression, apathy, personality change, suicidality



Woody Guthrie
PATIENT



Nancy Wexler & patient
PATIENT & HD RESEARCH PIONEER


Average lifespan shortened to
~10–30y¹
from diagnosis

Mid-40s
typical symptom onset,
during prime working years

50%
chance each child of an
affected parent inherits HD

>100K
symptomatic patients globally²

One Gene, Two Potential Culprits



One gene, two proteins

The mutant gene gives rise to full-length mutant HTT (67 exons) and a shorter, toxic isoform, HTT1a (exon 1 only)²

Both likely contribute to disease

Full-length mutant HTT and the shorter HTT1a isoform implicated as toxicity drivers^{2,4-6}

Many approaches miss HTT1a


Not all HTT-lowering strategies in development effectively address the shorter isoform^{1,7}

Brezosiran designed to reduce all HTT isoforms

Targets a conserved region in exon 1

Robust, Dose-Dependent CSF mHTT Reduction Demonstrated with SMC Assay

Up to 64% Mean Reduction at Month 3 and up to 80% Individual Reduction in CSF mHTT After a Single IT Dose of Brezosiran




mHTT reduction	Placebo (N=12)	Brezosiran				
		Dose 1 (N=5)	Dose 2 (N=4)	Dose 3 (N=9)	Dose 4 (N=9)	Dose 5 (N=9)
Mean maximum observed, % (SD) ^b	2.9 (25.5)	35.6 (18.0)	45.5 (15.7)	52.9 (22.5)	65.7 (11.8)	64.8 (10.2)
Minimum individual, % ^b	-36.8	19.0	23.5	6.7	49.3	52.0
Maximum individual, % ^b	60.8	63.2	59.7	79.6	80.7	77.2


^{a,b} Post-baseline values reported as less than the LLoQ are set to LLoQ/2, which is the case for 16 participants in figure a and 12 in table b. LLoQ = 26.5 fM. BL, baseline; CSF, cerebrospinal fluid; IT, intrathecal; LLoQ, lower limit of quantification; mHTT, mutant huntingtin; SD, standard deviation; SE, standard error; SMC, single molecule counting immunoassay.

Encouraging Safety & Tolerability Profile

CSF WBC



CSF NfL – Fold Change



Advancing Brezosiran to Pivotal Trial, Pending Regulatory Alignment

Phase 1 Open-Label Extension Study Continuing

ONGOING

Phase 1b study (adults with HD)

Single ascending dose study to characterize target engagement and safety of brezosiran

ONGOING

Phase 1b open-label extension study (adults with HD)

All participants eligible; repeat dosing every 6 months
Further characterizing safety of sustained HTT lowering and potential efficacy trends over time

PLAN TO INITIATE IN 2027

Pivotal, placebo-controlled efficacy study (adults with HD)

Definitive efficacy study to test whether brezosiran can slow HD progression

2026 Pipeline Goals to Drive Our Next Phase of Growth

Nucresiran	ATTR Amyloidosis	Advance TRITON-CM Phase 3 Trial	Ongoing
		Advance TRITON-PN Phase 3 Trial	Ongoing
Zilebesiran	Hypertension	Advance ZENITH Phase 3 Trial	Ongoing
Mivelsiran	Cerebral Amyloid Angiopathy	Complete Enrollment of cAPPricorn-1 Phase 2 Trial	H1 ✓
	Alzheimer's Disease	Initiate Phase 2 Trial	H1 ✓
ALN-6400	Bleeding Disorders	Initiate Phase 2 Trial in Second Bleeding Disorder	H1 ✓
		Phase 1 Data in Healthy Volunteers	ASH 2026
		Phase 2 Results in HHT	Q4'26 Earnings
ALN-4324	Type 2 Diabetes Mellitus	Initiate Phase 2 Trial	H1 ✓
Brezosiran	Huntington's Disease	Phase 1 Data	H2 ✓
ALN-2232	Obesity & Weight Management	Phase 1 Data	Q4'26 Earnings
Additional Programs		File 3-4 INDs	2026



Financial Summary

Jeff Poulton

Chief Financial Officer

Q3 2026 Financial Summary

(\$ in millions except where noted as percentages)	Q3 2025	Q3 2026	Q3 2026 vs Q3 2025 (Reported)	Q3 2026 vs Q3 2025 (CER ²)
<u>Total Net Product Revenues</u>	<u>\$851</u>	<u>\$1,292</u>	<u>52%</u>	<u>53%</u>
<u>Net Revenues from Collaborations & Royalties</u>	<u>398</u>	<u>166</u>	<u>-58%</u>	
Collaboration Revenue	352	71	-80%	
Royalty Revenue	46	95	105%	
<u>Total Revenues</u>	<u>1,249</u>	<u>1,458</u>	<u>17%</u>	<u>17%</u>
<u>Total Cost of Goods Sold, Collaborations & Royalties</u>	<u>200</u>	<u>362</u>		
Gross Margin on Product Revenues	77%	72%		
Gross Margin on Total Revenues	84%	75%		
<u>Non-GAAP Combined R&D and SG&A Expenses¹</u>	<u>573</u>	<u>671</u>	<u>17%</u>	
R&D	310	376	21%	
SG&A	263	296	13%	
<u>Non-GAAP Operating Income¹</u>	<u>476</u>	<u>425</u>	<u>-11%</u>	
Non-GAAP Operating Margin ¹	38%	29%		
<u>Non-GAAP Net Income¹</u>	<u>438</u>	<u>2,242</u>		

(\$ in millions)	Q4 2025	Q3 2026
Cash, Cash Equivalents & Marketable Securities (period end)	2,908	3,587

¹ Non-GAAP R&D expenses, Non-GAAP SG&A expenses, Non-GAAP operating income, Non-GAAP Operating Margin, and Non-GAAP Net Income are non-GAAP financial measures that exclude from the corresponding GAAP measures costs related to stock-based compensation expense and loss related to convertible debt. A reconciliation of these non-GAAP financial measures to the comparable GAAP measures, as well as additional information regarding our use of non-GAAP financial measures, are included in the Appendix to this presentation and in our press release dated October 29, 2026, which is accessible in the Investors section of our website at www.alnylam.com.

² CER growth rates represent growth at Constant Exchange Rates, a non-GAAP financial measure determined by comparing Q3 2026 performance (restated using Q3 2025 exchange rates) to actual Q3 2025 reported performance.

2026 Reiterated Full Year Guidance

Item	FY 2026 Guidance
Total Net Product Revenues¹	\$4,700 to \$5,100 million
Total Rare Net Product Revenues (GIVLAARI, OXLUMO)	\$500 to \$600 million
Total TTR Net Product Revenues (AMVUTTRA, ONPATTRO)	\$4,200 to \$4,500 million
<i>Net Product Revenues Growth vs. 2025 at Reported FX Rates¹</i>	57% to 71%
<i>Net Product Revenues Growth vs. 2025 at constant exchange rates (i.e., operational growth)²</i>	57% to 70%
Net Revenues from Collaborations & Royalties	\$575 to \$625 million
Non-GAAP Combined R&D and SG&A Expenses³	\$2,700 to \$2,800 million

¹ Our 2026 FY Guidance is based upon June 30, 2026 FX rates including 1 EUR = 1.14 USD and 1 USD = 162 JPY

² CER = constant exchange rate, representing growth calculated as if exchange rates had remained unchanged from those used in 2025. CER is a non-GAAP financial measure

³ 2026 Non-GAAP Combined R&D and SG&A Expenses guidance is a non-GAAP financial measure that excludes from the corresponding GAAP measure stock-based compensation expense estimated at \$330M - \$380M.



Q&A Session

Q3 2026 Financial Results

Poised for Continued Growth



**Commercial
Execution**



**Pipeline
Momentum**



**Progress Toward
*Alnylam 2030***

A photograph of two women sitting at a table in a dimly lit room, possibly a kitchen or dining area. The woman on the left is older with grey hair, wearing a white and red patterned cardigan over a blue top. The woman on the right is younger with dark hair, wearing a green and white patterned cardigan over a blue top. They are both laughing heartily, looking towards the right. The background is dark with some kitchen items visible on a counter. A warm light source is visible behind them, creating a soft glow.

Silence disease

Amplify life™

 Alnylam®




Appendix

Q3 2026 Financial Results

Q3 2026: Sustained Rare Franchise Performance



\$142M
Total Rare
Global Q3 2026
Net Product Revenues



Q3 2026 Rare Franchise Highlights

	QoQ % Growth	YoY % Growth
GIVLAARI	0%	21%
OXLUMO	1%	(1%)
TOTAL Rare	0%	12%

- GIVLAARI YoY +21% growth highlights:
 - Primarily driven by increase in global patients on therapy and timing of orders in partner markets
- OXLUMO YoY -1% growth highlights:
 - Primarily driven by increase in global patients on therapy offset by lower net price and timing of orders in partner markets

Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	September 30, 2026	September 30, 2025
Reconciliation of GAAP to Non-GAAP Research and development expenses:		
GAAP Research and development expenses	\$ 408,538	\$ 358,814
Less: Stock-based compensation expenses	(32,861)	(48,725)
Non-GAAP Research and development expenses	<u>\$ 375,677</u>	<u>\$ 310,089</u>
Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses:		
GAAP Selling, general and administrative expenses	\$ 342,000	\$ 322,076
Less: Stock-based compensation expenses	(46,257)	(59,486)
Non-GAAP Selling, general and administrative expenses	<u>\$ 295,743</u>	<u>\$ 262,590</u>
Reconciliation of GAAP to Non-GAAP Income (loss) from operations:		
GAAP Income from operations	\$ 345,798	\$ 367,982
Add: Stock-based compensation expenses	79,118	108,211
Non-GAAP Operating income	<u>\$ 424,916</u>	<u>\$ 476,193</u>
Reconciliation of GAAP to Non-GAAP Net income (loss):		
GAAP Net income	\$ 2,167,335	\$ 292,683
Add: Stock-based compensation expenses	79,118	108,211
Add: Loss related to convertible debt	—	39,146
Less: Income tax effect of GAAP to non-GAAP reconciling items	(4,543)	(2,261)
Non-GAAP Net income	<u>\$ 2,241,910</u>	<u>\$ 437,779</u>

Please note that the figures presented above may not sum exactly due to rounding

Anylam Pharmaceuticals, Inc.

Reconciliation of Product Revenue and Growth at Constant Currency

	September 30, 2026
	Three Months Ended
AMVUTTRA net product revenue growth, as reported	65 %
Add: Impact of foreign currency translation	1
AMVUTTRA net product revenue growth at constant currency	66 %
ONPATTRO net product revenue growth, as reported	(50)%
Add: Impact of foreign currency translation	—
ONPATTRO net product revenue growth at constant currency	(50)%
Total TTR net product revenue growth, as reported	59 %
Add: Impact of foreign currency translation	1
Total TTR net product revenue growth at constant currency	60 %
GIVLAARI net product revenue growth, as reported	21 %
Add: Impact of foreign currency translation	1
GIVLAARI net product revenue growth at constant currency	22 %
OXLUMO net product revenue growth, as reported	(1)%
Add: Impact of foreign currency translation	1
OXLUMO net product revenue growth at constant currency	— %
Total Rare net product revenue growth, as reported	12 %
Add: Impact of foreign currency translation	1
Total Rare net product revenue growth at constant currency	13 %
Total net product revenue growth, as reported	52 %
Add: Impact of foreign currency translation	1
Total net product revenue growth at constant currency	53 %
Total revenue growth, as reported	17 %
Add: Impact of foreign currency translation	—
Total revenue growth at constant currency	17 %